Issue 4/2012

  • Can bioeconomy save the planet?

    In this issue:

    • Swiss Biotech Report reveals more investment in sector
    • Danes kick-off psychiatric genomics research hub
    • Wellcome Trust to aid UK biotech with £200m in funding
    • Analytica 2012 in Munich: Update on bioanalytics
    • Janus to commercialise inclusion body drug delivery system
    • Mabion announces IPO on Warsaw Stock Exchange
    • Intratumour heterogeneity challenges biomarker approach

Volume 2016

Volume 2015

Volume 2014

Volume 2013

Volume 2012

© 2007-2016 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/4/pos/1.html?sort=desc&cHash=8305edff5982cb307c5ea48106acb36a

Kurszettel

Alle Kurse

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • NORDIC NANOVECTOR (N)27.10 NOK10.61%

FLOP

  • THERAMETRICS (CH)0.02 CHF-33.33%
  • 4SC (D)2.38 EUR-8.11%
  • RENEURON (UK)3.38 GBP-3.43%

TOP

  • GALAPAGOS (B)51.60 EUR30.0%
  • NICOX (F)10.95 EUR28.1%
  • GENMAB (DK)1194.00 DKK24.0%

FLOP

  • THERAMETRICS (CH)0.02 CHF-33.3%
  • 4SC (D)2.38 EUR-27.9%
  • MOBERG PHARMA (S)38.70 SEK-20.4%

TOP

  • KARO BIO (S)30.30 SEK1961.2%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • NICOX (F)10.95 EUR488.7%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.25 SEK-89.0%
  • BB BIOTECH (D)44.70 EUR-84.3%
  • BIOTEST (D)17.05 EUR-78.3%

No liability assumed, Date: 30.05.2016